Sign in Create account

Auro Laboratories Ltd.

Healthcare · Pharmaceuticals & Biotechnology

BSE: 530233
₹245.00
▲ 0.00 (0.00%)
Sept. 30, 2026 · BSE · bse_bhavcopy
Quality
37/100
Weak
Valuation
55/100
Fairly Valued
Momentum
51/100
Neutral

QVM read Mixed signals Quality Weak, Valuation Fairly Valued, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹153 Cr
PE (TTM)
32.6
Industry median 36.1 (152 companies)
Price to Book
3.3
PEG (TTM)
0.1
Institutions holding %
Data unavailable.
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
Data unavailable.
Relative return vs Sector, qtr %
-11.5
Free Cash Flow
₹-55 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
1088.24%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
61.59%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
125.54%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
1096.19%
as of June 30, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
216.08%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
1.08
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
1.37
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
2.13
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
11.93%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
28.51%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
30.91%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
0.84%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
9.79%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
2.20%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

2 of 6 met
  • Yes Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • No Debt to equity is below 0.5 (1.37)
  • No Return on equity is 15% or more (2.2%)
  • Yes Net cash flow for the latest year is positive
  • No Cash from operations is higher than the year before

Ownership

2 of 3 met
  • No FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

2 of 3 met
  • No 1-year return beats the industry median
  • Yes Revenue growth beats the industry median
  • Yes Profit growth beats the industry median

Value and momentum

2 of 6 met
  • Yes Price sits in the Buy zone of its own historical PE range (Buy Zone)
  • No Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • Yes Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs SENSEX)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
0.0%
Low 235.0500 · High 249.0000
1W return
-2.3%
Low 230.0000 · High 256.0000
1M return
4.1%
Low 226.0000 · High 267.8000
52W return
-11.5%
Low 223.1000 · High 267.8000
Lifetime High ₹292.6000 (May 6, 2024)
Lifetime Low ₹1.9500 (May 14, 2009)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish5
Bearish1
5D
243.9
10D
245.2
20D
244.8
50D
236.1
100D
219.4
200D
182.5

Delivery and volume

Day avg. delivery
67.9%
Week avg. delivery
80.5%
Month avg. delivery
64.6%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

243.02
Pivot
First resistance250.98
Second resistance256.97
Third resistance264.93
First support237.03
Second support229.07
Third support223.08
Day RSI51.6
Day MFI17.8
Day MACD1.97
Day MACD signal3.85

Beta

1M0.67
3M0.59
1Y0.59
3Y0.49

Price change analysis

↑ 4.1%
Over 1 Month
LowHigh
226.00267.80
↓ -11.5%
Over 3 Months
LowHigh
223.10267.80
↓ -11.5%
Over 6 Months
LowHigh
223.10267.80
↓ -11.5%
Over 1 Year
LowHigh
223.10267.80
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 32.6 (own history: 13.0–249.3)
Buy Zone

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹9 Cr
Net profit (June 30, 2026)
₹1 Cr
Basic EPS (June 30, 2026)
₹1.6800

Ranks #128 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter52.40%
  • Mutual funds0.01%

Largest holders

Data unavailable.

Historical promoter holding

Promoters holdings increased from 52.18% to 52.40% in Jun 2026 qtr

Historical mutual fund holding

Mutual funds holdings were unchanged at 0.01% in Jun 2026 qtr

All shareholding details →

Deals (Bulk & Block)

All 9 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
31 Aug 2023 PADRONE MARKETING PVT LTD Bulk Buy 50,000 134.8700 BSE
30 Jun 2023 AMIT DHANYAKUMAR CHORDIA Bulk Sell 31,240 80.7800 BSE
18 May 2023 AMIT DHANYAKUMAR CHORDIA Bulk Buy 50,000 97.6400 BSE
10 Jan 2022 VIVEK MEHROTRA Bulk Sell 41,944 140.9700 BSE
12 Apr 2021 JAYSHREE VINOD SHAH Bulk Sell 67,656 80.3400 BSE
17 Dec 2013 MEENA SHARAT DEORAH Bulk Buy 100,000 5.8000 BSE
17 Dec 2013 SHARAT . DEORAH Bulk Buy 100,000 5.8000 BSE
17 Dec 2013 JAYSHREE VINOD SHAH Bulk Sell 200,000 5.8000 BSE
22 Aug 2012 SNEHALATHA SINGHI Bulk Sell 41,322 6.5500 BSE

All bulk and block deals →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Strong revenue growth YoY (216.1%)

Weaknesses

  • Low Return on Equity (2.2%)
  • High financial leverage (Debt/Equity 1.37)

Opportunities

  • PEG below 1 (0.06) -- earnings growth outpacing its own valuation

Threats

Data unavailable.

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Auro Laboratories Ltd.

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.